Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMorningStar·5 hours agoALNY-28.31%
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanksbenzinga_article·8 hours agoALNY-28.31%AZN-1.13%
Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPSMarket Beat·8 hours agoALNY-28.31%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·9 hours agoINO-36.92%ALNY-28.31%
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Viewsbenzinga_article·10 hours agoXRX+32.20%BMY+2.79%
U.S. stock market update: Alnylam Pharma falls 26.98%, stock price plummets due to lowered revenue expectationsPrice Alert·12 hours agoALNY-28.31%
Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 52-Week Low - Should You Sell?Market Beat·12 hours agoALNY-28.31%
Alnylam Pharma Reports Net Income In Q2; Revises 2026 TTR Net Product Revenue Guidancerttnews·13 hours agoALNY-28.31%
ALNYLAM PHARMACEUTICALS, INC. 2Q 2026: Revenue $1.29B, EPS $1.21— 10-Q SummaryTradingView·14 hours agoALNY-28.31%
